Rockefeller Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rockefeller Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.1M	Sell	235,832 -225	-0.1%	-$28.1K	0.05%	331
2025 Q4	$28.8M	Buy	236,057 +72,636	+44%	+$8.33M	0.05%	342
2025 Q3	$16.4M	Sell	163,421 -7,333	-4%	-$660K	0.03%	477
2025 Q2	$14.2M	Sell	170,754 -767	-0.4%	-$61.2K	0.03%	497
2025 Q1	$13.9M	Sell	171,521 -21,124	-11%	-$1.89M	0.03%	466
2024 Q4	$17.3M	Buy	192,645 +14,142	+8%	+$1.37M	0.04%	382
2024 Q3	$17.6M	Buy	178,503 +52,525	+42%	+$5.16M	0.05%	380
2024 Q2	$11.7M	Buy	125,978 +11,524	+10%	+$1.03M	0.03%	463
2024 Q1	$10.9M	Buy	114,454 +12,950	+13%	+$1.2M	0.03%	476
2023 Q4	$9.06M	Buy	101,504 +865	+0.9%	+$64.2K	0.03%	484
2023 Q3	$7.35M	Sell	100,639 -5,442	-5%	-$435K	0.03%	497
2023 Q2	$8.83M	Buy	106,081 +173	+0.2%	+$14.5K	0.03%	469
2023 Q1	$8.07M	Sell	105,908 -165,110	-61%	-$13.7M	0.03%	469
2022 Q4	$22.5M	Buy	271,018 +175,429	+184%	+$14.2M	0.11%	204
2022 Q3	$7.58M	Buy	95,589 +11,525	+14%	+$972K	0.04%	434
2022 Q2	$6.24M	Buy	84,064 +5,482	+7%	+$412K	0.03%	456
2022 Q1	$7.06M	Buy	78,582 +30,323	+63%	+$2.8M	0.03%	458
2021 Q4	$5.4M	Buy	48,259 +13,918	+41%	+$1.68M	0.03%	517
2021 Q3	$4.32M	Buy	34,341 +16,224	+90%	+$2.09M	0.02%	511
2021 Q2	$2.45M	Buy	18,117 +8,022	+79%	+$1.05M	0.01%	661
2021 Q1	$1.37M	Sell	10,095 -49,372	-83%	-$7.39M	0.01%	692
2020 Q4	$8.37M	Buy	59,467 +56,148	+1,692%	+$7.19M	0.06%	247
2020 Q3	$369K	Buy	3,319 +715	+27%	+$80.2K	﹤0.01%	873
2020 Q2	$292K	Buy	2,604 +1,100	+73%	+$108K	﹤0.01%	855
2020 Q1	$116K	Buy	1,504 +204	+16%	+$18.1K	﹤0.01%	978
2019 Q4	$124K	Buy	1,300 +800	+160%	+$69.2K	﹤0.01%	905
2019 Q3	$38K	Sell	500 -2,992	-86%	-$249K	﹤0.01%	1055
2019 Q2	$306K	Buy	+3,492	New	+$298K	﹤0.01%	517
2019 Q1	–	Sell	-24,705	Closed	-$1.77M	–	1942
2018 Q4	$1.77M	Buy	+24,705	New	+$1.99M	0.03%	196
2018 Q3	–	Sell	-1,365	Closed	-$130K	–	790
2018 Q2	$130K	Buy	+1,365	New	+$125K	﹤0.01%	367

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rockefeller Capital Management's XBI Position: Q1 2026 in Review

Rockefeller Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.1% in Q1 2026, selling an estimated $28.1K and leaving 235,832 shares worth $30.1M. The position accounts for 0.05% of the portfolio, ranked #331.

Rockefeller Capital Management first reported a position in XBI in Q2 2018 and has held it in 30 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Rockefeller Capital Management held 235,832 shares of State Street SPDR S&P Biotech ETF worth $30.1M as of Q1 2026.
Rockefeller Capital Management sold 225 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $28.1K.
State Street SPDR S&P Biotech ETF made up 0.05% of Rockefeller Capital Management's portfolio in Q1 2026, its #331 holding.
Rockefeller Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 30 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.